Thyroid hormones and their membrane receptors as therapeutic targets for T cell lymphomas

• Autores: Cremaschi, Graciela A.; Cayrol, María Florencia; Sterle, Helena Andrea; Díaz Flaqué, María Celeste; Barreiro Arcos, María Laura
• Año de publicación: 2016
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: Postprint del documento publicado en Pharmacological Research, 2016; 109: 55-63
• Materia: MEDICINA; INMUNOLOGIA; GLANDULA TIROIDES; HORMONAS
• Institución: Pontificia Universidad Católica Argentina

Fil: Cremaschi, Graciela A. Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cremaschi, Graciela A. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Laboratorio de Radioisótopos; Argentina
Fil: Sterle, Helena Andrea. Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Díaz Flaqué, María Celeste. Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Barreiro Arcos, María Laura. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina
Abstract: Thyroid hormones (THs) are important regulators of metabolism, differentiation and cell proliferation.They can modify the physiology of human and murine T cell lymphomas (TCL). These effects involvegenomic mechanisms, mediated by specific nuclear receptors (TR), as well as nongenomic mechanisms,that lead to the activation of different signaling pathways through the activation of a membrane recep-tor, the integrin v3. Therefore, THs are able to induce the survival and growth of TCL. Specifically, thesignaling induced by THs through the integrin v3 activates proliferative and angiogenic programs,mediated by the regulation of the vascular endothelial growth factor (VEGF). The genomic or pharmaco-logic inhibition of integrin v3 reduces the production of VEGF and induces cell death both in vitro andin xenograft models of human TCL.Here we review the mechanisms involved in the modulation of the physiology of TCL induced by THs,the analysis of the interaction between genomic and nongenomic actions of THs and their contribution toT cell lymphomagenesis. These actions of THs suggest a novel mechanism for the endocrine modulationof the physiopathology of TCL and they provide a potential molecular target for its treatment.